Total Liabilities for Alnylam Pharmaceuticals (ALNY)
According to Alnylam Pharmaceuticals's latest reported financial statements, the company's latest reported total liabilities is $4.18B USD. Total liabilities sum everything the company owes at the end of each reporting period — accounts payable, accrued expenses, debt, lease obligations, and other claims — as filed on the balance sheet. Compare with total assets and net assets for solvency context.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingTotal LiabilitiesSwitch metric
Latest period
$4.18B
YoY change
+0.1%
5Y CAGR
+11.8%
Peak year (2025)
$4.18B
Latest annual
$4.18B
Total Liabilities history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Total Liabilities history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| Fiscal year | Period ended | Reported | Total Liabilities | YoY |
|---|---|---|---|---|
| 2025 | $4.18B | +0.1% | ||
| 2024 | $4.17B | +3.0% | ||
| 2023 | $4.05B | +9.3% | ||
| 2022 | $3.70B | +21.3% | ||
| 2021 | $3.06B | +27.8% | ||
| 2020 | $2.39B | +150.0% | ||
| 2019 | $956.44M | +250.6% | ||
| 2018 | $272.84M | +19.5% | ||
| 2017 | $228.30M | -33.4% | ||
| 2016 | $342.59M | +181.3% | ||
| 2015 | $121.80M | -15.0% | ||
| 2014 | $143.33M | -4.6% | ||
| 2013 | $150.18M | -2.1% | ||
| 2012 | $153.47M | -6.4% | ||
| 2011 | $163.92M | -30.3% | ||
| 2010 | $235.03M | -22.5% | ||
| 2009 | $303.42M | -13.9% | ||
| 2008 | $352.55M | +19.7% | ||
| 2007 | $294.62M | +658.7% | ||
| 2006 | $38.83M | +6.2% | ||
| 2005 | $36.57M | +83.2% | ||
| 2004 | $19.96M | -67.7% | ||
| 2003 | $61.89M | +198.2% | ||
| 2002 | $20.76M | — |
Total Liabilities values are taken from Alnylam Pharmaceuticals's reported balance sheets (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
2025's annual total liabilities for Alnylam Pharmaceuticals (ALNY) came in at $4.18B – edged up 0.1% year-over-year.
Over 2020–2025 (5 years), Alnylam Pharmaceuticals total liabilities expanded at a +11.8% compound annual rate, with the latest reading among the more recent periods of the dataset.
The highest annual total liabilities of $4.18B was reported in 2025. The lowest in the available history was $19.96M in 2004.
Among 8 Healthcare peers, Alnylam Pharmaceuticals (ALNY) ranks 9th; the peer median for total liabilities is $101.80B.
Alnylam Pharmaceuticals Total Liabilities by Year
Alnylam Pharmaceuticals Total Liabilities 2025: $4.18B
Alnylam Pharmaceuticals total liabilities in 2025 was $4.18B, edged up 0.1% from 2024. This figure represents the highest annual value in the available history.
Alnylam Pharmaceuticals Total Liabilities 2024: $4.17B
Alnylam Pharmaceuticals total liabilities in 2024 was $4.17B, edged up 3.0% from 2023.
Alnylam Pharmaceuticals Total Liabilities 2023: $4.05B
Alnylam Pharmaceuticals total liabilities in 2023 was $4.05B, grew 9.3% from 2022.
Alnylam Pharmaceuticals Total Liabilities 2022: $3.70B
Alnylam Pharmaceuticals total liabilities in 2022 was $3.70B, grew 21.3% from 2021.
Alnylam Pharmaceuticals Total Liabilities 2021: $3.06B
Alnylam Pharmaceuticals total liabilities in 2021 was $3.06B.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers — Total Liabilities
Companies in the same sector as Alnylam Pharmaceuticals, ranked by their latest total liabilities.
| Company | Total Liabilities | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $348.86B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $207.88B | Healthcare |
| AbbVie Inc. (ABBV) | $137.19B | Healthcare |
| Johnson & Johnson (JNJ) | $117.67B | Healthcare |
| Eli Lilly and Company (LLY) | $85.94B | Healthcare |
| Merck & Co., Inc. (MRK) | $84.20B | Healthcare |
| Amgen Inc. (AMGN) | $81.93B | Healthcare |
| AstraZeneca PLC (AZN) | $65.36B | Healthcare |
Frequently asked questions
What is Alnylam Pharmaceuticals's total liabilities?
- Latest reported total liabilities for Alnylam Pharmaceuticals (ALNY) is $4.18B (period ending December 31, 2025).
How has Alnylam Pharmaceuticals total liabilities changed year-over-year?
- Alnylam Pharmaceuticals (ALNY) total liabilities changed +0.1% year-over-year on the latest annual filing.
What is the long-term growth rate of Alnylam Pharmaceuticals total liabilities?
- Alnylam Pharmaceuticals (ALNY) total liabilities compound annual growth rate is +11.8% over the most recent 5 years available.
When did Alnylam Pharmaceuticals total liabilities hit its highest annual value?
- Alnylam Pharmaceuticals total liabilities reached its highest annual value of $4.18B in 2025.
What was Alnylam Pharmaceuticals total liabilities in 2024?
- Alnylam Pharmaceuticals (ALNY) total liabilities in 2024 was $4.17B.
What was Alnylam Pharmaceuticals total liabilities in 2025?
- Alnylam Pharmaceuticals (ALNY) total liabilities in 2025 was $4.18B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
ALNY Overview
Company profile, financial tools, and key metrics
ALNY Revenue Counter
Earns $117.77 every second. See per minute, hour, and day.
ALNY Earnings Counter
Earns $9.95 per second net profit. See per minute, hour, and day.
ALNY Economic Scale
Exceeds Curacao's GDP. Compare with world economies.
ALNY What If Invested
What if you had invested $1,000? See historical returns from any date.
ALNY How It Makes Money
Discover visual breakdown of $3.71B in revenue — where it comes from and where it goes.
ALNY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
ALNY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
ALNY Daily Price Character
Explosive · 50.6% historical win rate (green days). Streaks & record days.
ALNY Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.